JP2011241213A5 - - Google Patents

Download PDF

Info

Publication number
JP2011241213A5
JP2011241213A5 JP2011110037A JP2011110037A JP2011241213A5 JP 2011241213 A5 JP2011241213 A5 JP 2011241213A5 JP 2011110037 A JP2011110037 A JP 2011110037A JP 2011110037 A JP2011110037 A JP 2011110037A JP 2011241213 A5 JP2011241213 A5 JP 2011241213A5
Authority
JP
Japan
Prior art keywords
aqueous
type
insulin
diabetes
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011110037A
Other languages
English (en)
Other versions
JP2011241213A (ja
JP5269945B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011241213A publication Critical patent/JP2011241213A/ja
Publication of JP2011241213A5 publication Critical patent/JP2011241213A5/ja
Application granted granted Critical
Publication of JP5269945B2 publication Critical patent/JP5269945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (17)

  1. ２００−１０００Ｕ／ｍＬ［２００−１０００ＩＵ ヒトインスリンと等モル］のインスリングラルギンを含むが、ただし製剤のインスリングラルギンの濃度は６８４Ｕ／ｍＬではない水性医薬製剤。
  2. ２７０−３３０Ｕ／ｍＬのインスリングラルギン［２７０−３３０ＩＵ ヒトインスリンと等モル］を含む、請求項１に記載の水性製剤。
  3. ３００Ｕ／ｍＬのインスリングラルギン［３００ＩＵヒトインスリンと等モル］を含む、請求項２に記載の水性製剤。
  4. エキセンジン−４のアナログを含む、請求項１〜３のいずれか１項に記載の水性医薬製剤。
  5. エキセンジン−４のアナログが、リキシセナチド、エクセナチドおよびリラグルチドを含む群より選択される、請求項４に記載の水性製剤。
  6. インスリングラルギン１Ｕあたり０.１μｇ〜１０μｇのリキシセナチドを含む、請求項５に記載の水性製剤。
  7. 亜鉛、ｍ−クレゾール、グリセリン、ポリソルベート２０およびナトリウムを含む群より選択される１種またはそれ以上の賦形剤を含む請求項１〜６のいずれか１項に記載の水性製剤。
  8. ９０μｇ／ｍＬの亜鉛、２.７ｍｇ／ｍｌのｍ−クレゾールおよび２０ｍｇ／ｍｌのグリセリン８５％を含む、請求項７に記載の水性製剤。
  9. ９０μｇ／ｍＬの亜鉛、２.７ｍｇ／ｍｌのｍ−クレゾール、２０μｇ／ｍＬのポリソルベート２０および２０ｍｇ／ｍｌのグリセリン８５％を含む、請求項７に記載の水性製剤。
  10. ｐＨが３.４〜４.６である、請求項１〜９のいずれか１項に記載の水性製剤。
  11. ｐＨが４である、請求項１０に記載の水性製剤。
  12. ｐＨが４.５である、請求項１０に記載の水性製剤。
  13. 患者のＩ型およびII型糖尿病を治療するための、請求項１〜１２のいずれか１項に記載の水性製剤。
  14. 患者のＩ型およびII型糖尿病の治療において、長時間作用型インスリン曝露の持続時間を延長するための、請求項１〜１２のいずれか１項に記載の水性製剤。
  15. 長時間作用型インスリンによる患者のＩ型およびII型糖尿病の治療において、低血糖の発生を減少させるための、請求項１〜１２のいずれか１項に記載の水性製剤。
  16. 患者のＩ型およびII型糖尿病の治療において、ピークレス長時間作用型基礎インスリンを与えるための、請求項１〜１２のいずれか１項に記載の水性製剤。
  17. Ｉ型糖尿病およびII型糖尿病の治療のための医薬品の製造のための、請求項１〜１６のいずれか１項に記載の水性製剤の使用。
JP2011110037A 2010-05-19 2011-05-17 インスリングラルギンの長時間作用型製剤 Active JP5269945B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP10305532 2010-05-19
EP10305532.3 2010-05-19
EP10305780 2010-07-13
EP10305780.8 2010-07-13
EP11305140.3 2011-02-10
EP11305140 2011-02-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013097274A Division JP2013147509A (ja) 2010-05-19 2013-05-07 インスリングラルギンの長時間作用型製剤

Publications (3)

Publication Number Publication Date
JP2011241213A JP2011241213A (ja) 2011-12-01
JP2011241213A5 true JP2011241213A5 (ja) 2012-12-27
JP5269945B2 JP5269945B2 (ja) 2013-08-21

Family

ID=44148980

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011110037A Active JP5269945B2 (ja) 2010-05-19 2011-05-17 インスリングラルギンの長時間作用型製剤
JP2013097274A Withdrawn JP2013147509A (ja) 2010-05-19 2013-05-07 インスリングラルギンの長時間作用型製剤
JP2015112917A Active JP6333775B2 (ja) 2010-05-19 2015-06-03 インスリングラルギンの長時間作用型製剤
JP2017238185A Pending JP2018044003A (ja) 2010-05-19 2017-12-13 インスリングラルギンの長時間作用型製剤
JP2019224977A Pending JP2020040990A (ja) 2010-05-19 2019-12-13 インスリングラルギンの長時間作用型製剤

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013097274A Withdrawn JP2013147509A (ja) 2010-05-19 2013-05-07 インスリングラルギンの長時間作用型製剤
JP2015112917A Active JP6333775B2 (ja) 2010-05-19 2015-06-03 インスリングラルギンの長時間作用型製剤
JP2017238185A Pending JP2018044003A (ja) 2010-05-19 2017-12-13 インスリングラルギンの長時間作用型製剤
JP2019224977A Pending JP2020040990A (ja) 2010-05-19 2019-12-13 インスリングラルギンの長時間作用型製剤

Country Status (43)

Country Link
US (11) US20110301081A1 (ja)
EP (9) EP2387989B1 (ja)
JP (5) JP5269945B2 (ja)
KR (4) KR101989343B1 (ja)
CN (5) CN107583038A (ja)
AR (1) AR081200A1 (ja)
AU (1) AU2011202239C1 (ja)
BR (2) BR122019006884B1 (ja)
CA (1) CA2792669C (ja)
CL (1) CL2012003197A1 (ja)
CO (1) CO6640217A2 (ja)
CR (1) CR20120578A (ja)
CY (3) CY1115649T1 (ja)
DK (3) DK2781212T3 (ja)
DO (1) DOP2012000261A (ja)
EC (1) ECSP12012298A (ja)
ES (4) ES2945208T3 (ja)
GT (1) GT201200287A (ja)
HK (5) HK1210435A1 (ja)
HR (3) HRP20140860T1 (ja)
HU (2) HUE039355T2 (ja)
IL (2) IL221964A (ja)
JO (2) JO2944B1 (ja)
LT (2) LT2781212T (ja)
MA (1) MA34224B1 (ja)
MX (2) MX343489B (ja)
MY (1) MY156188A (ja)
NI (1) NI201200152A (ja)
NZ (1) NZ602541A (ja)
PE (2) PE20130511A1 (ja)
PH (2) PH12015501421A1 (ja)
PL (4) PL2781212T3 (ja)
PT (3) PT2781212T (ja)
RS (1) RS53559B1 (ja)
RU (3) RU2564104C2 (ja)
SG (2) SG185593A1 (ja)
SI (3) SI2781212T1 (ja)
TN (1) TN2012000478A1 (ja)
TR (2) TR201809475T4 (ja)
TW (4) TW201735941A (ja)
UY (1) UY33391A (ja)
WO (1) WO2011144673A2 (ja)
ZA (1) ZA201206998B (ja)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2505593A1 (en) 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
PL2229407T3 (pl) 2008-01-09 2017-06-30 Sanofi-Aventis Deutschland Gmbh Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
SG10201403840VA (en) * 2009-07-06 2014-10-30 Sanofi Aventis Deutschland Aqueous insulin preparations containing methionine
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
EP3345593B1 (de) 2009-11-13 2023-09-06 Sanofi-Aventis Deutschland GmbH Pharmazeutische zusammensetzung umfassend despro36exendin-4(1-39)-lys6-nh2 und methionin
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
JP6375113B2 (ja) 2011-01-28 2018-08-15 サノフィ・バイオテクノロジー 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9089476B2 (en) 2011-08-10 2015-07-28 Adocia Injectable solution at pH 7 comprising at least one basal insulin whose PI is between 5.8 and 8.5
FR2984749A1 (fr) * 2011-12-23 2013-06-28 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique
TWI608847B (zh) 2011-08-29 2017-12-21 賽諾菲阿凡提斯德意志有限公司 用於控制糖尿病二型病患血糖的醫藥組合物
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
FR2985429B1 (fr) * 2012-01-09 2016-07-29 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
FR2985428B1 (fr) * 2012-01-09 2016-05-27 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
CN104114155B (zh) * 2012-01-09 2019-02-15 阿道恰公司 Ph为7并且至少包含pi为5.8至8.5之基础胰岛素和经取代共聚(氨基酸)的可注射溶液
WO2013158277A1 (en) * 2012-04-18 2013-10-24 Waters Technologies Corporation Methods for quantifying polypeptides using mass spectrometry
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001896B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
FR3001895B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
JP6111475B2 (ja) * 2012-12-19 2017-04-12 ウォックハート リミテッド ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物
AU2013360721A1 (en) 2012-12-21 2015-07-09 Sanofi Exendin-4 Derivatives as dual GLP1/GIP or trigonal GLP1/GIP/Glucagon Agonists
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
CN104870469A (zh) * 2012-12-26 2015-08-26 沃克哈特有限公司 药物组合物
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2014147141A1 (en) * 2013-03-20 2014-09-25 Novo Nordisk A/S Insulin dosing regimen
CN105142661B (zh) 2013-04-03 2019-08-16 赛诺菲 通过长效胰岛素制剂治疗糖尿病
US20220202711A1 (en) * 2013-04-03 2022-06-30 Sanofi Treatment of Diabetes Mellitus by Long-Acting Formulations of Insulins
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
CA2915413A1 (en) * 2013-06-17 2014-12-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
CN104587455A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种胰岛素制剂
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080155A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
KR20160101195A (ko) 2014-01-09 2016-08-24 사노피 인슐린 아스파트의 안정화된 약제학적 제형
CN103830189A (zh) * 2014-03-04 2014-06-04 山东新时代药业有限公司 一种重组甘精胰岛素制剂及其制备方法
JP2017515797A (ja) 2014-04-04 2017-06-15 サノフイ 糖尿病、肥満、脂質異常症および関連障害の治療のためのｇｐｒ１１９モジュレーターとしての置換インダノン化合物
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
TW201625605A (zh) 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
EP3677277A1 (en) 2014-07-16 2020-07-08 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
PE20171622A1 (es) * 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
CN104688677B (zh) * 2015-02-05 2018-02-09 通化东宝药业股份有限公司 一种稳定的甘精胰岛素注射液及其制备方法
CN104688678B (zh) * 2015-02-05 2017-11-17 通化东宝药业股份有限公司 一种甘精胰岛素注射液的制备方法及其制备的甘精胰岛素注射液
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
EA039114B1 (ru) * 2015-11-10 2021-12-06 Санофи-Авентис Дойчланд Гмбх Применение композиции с постоянным соотношением инсулин гларгин/ликсисенатид для лечения сахарного диабета 2 типа
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
CN105597087B (zh) * 2016-01-06 2019-04-26 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
WO2018055539A1 (en) 2016-09-22 2018-03-29 Wockhardt Limited Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
JP7309606B2 (ja) 2016-12-22 2023-07-18 サノフイ 活性比が最適化されたｆｇｆ２１化合物／ｇｌｐ－１ｒアゴニスト組合せ物
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
DK4019039T3 (da) * 2017-07-27 2024-01-15 Adocia Sammensætninger i form af en injicerbar vandig opløsning, som omfatter mindst et humant insulin A21G og en glucagonundertrykker med prandial virkning
TW202015735A (zh) 2018-05-30 2020-05-01 法商賽諾菲公司 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物
EP3810183A1 (en) 2018-06-21 2021-04-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
WO2019243628A1 (fr) 2018-06-22 2019-12-26 Adocia Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US20220233784A1 (en) 2019-05-29 2022-07-28 Sanofi Drug delivery device
WO2021235916A1 (ko) * 2020-05-22 2021-11-25 한미약품 주식회사 글루카곤, glp-1 및 gip 삼중 활성체의 지속형 결합체의 액상 제제
WO2022002408A1 (en) 2020-07-02 2022-01-06 Sanofi Glp-1r agonist / fgf21 fusion proteins
JP2023540662A (ja) 2020-07-02 2023-09-26 サノフイ 低減された活性を有するｇｌｐ－１ｒアゴニストペプチド
EP4196145A1 (en) * 2020-08-14 2023-06-21 Kyon Biotech AG Increasing the efficacy of biological therapeutic molecules

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960702A (en) 1985-09-06 1990-10-02 Codon Methods for recovery of tissue plasminogen activator
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
CH682806A5 (de) * 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
CH682805A5 (de) * 1992-02-24 1993-11-30 Medimpex Ets Anzeigeeinrichtung für ein Injektionsgerät.
EP0748213B1 (en) 1994-03-07 2004-04-14 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
PE79099A1 (es) 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
IL134901A0 (en) 1997-10-24 2001-05-20 Lilly Co Eli Insoluble insulin compositions
US6978471B1 (en) 1999-05-25 2005-12-20 Thomson Licensing S.A. System for acquiring and processing broadcast programs and program guide data
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
DE60134251D1 (de) 2000-09-18 2008-07-10 Sanos Bioscience As Verwendung von glp-2-peptiden
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
US20030026872A1 (en) 2001-05-11 2003-02-06 The Procter & Gamble Co. Compositions having enhanced aqueous solubility and methods of their preparation
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
JP2005508895A (ja) * 2001-08-28 2005-04-07 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１および基礎インスリンの予備混合物
US20100069293A1 (en) 2002-02-27 2010-03-18 Pharmain Corporation Polymeric carrier compositions for delivery of active agents, methods of making and using the same
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP1525219B1 (en) 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 and methods for treating diabetes
DE10235168A1 (de) 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
WO2004064662A2 (en) 2003-01-21 2004-08-05 Ortho-Tain Inc Orthodontic appliance
GB0304822D0 (en) * 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
EA200501421A1 (ru) 2003-03-04 2006-04-28 Дзе Текнолоджи Девелопмент Компани Лтд. Пероральная композиция инсулина и способы её изготовления и применения
WO2005020927A2 (en) 2003-08-29 2005-03-10 Centocor, Inc. Method of promoting graft survival with anti-tissue factor antibodies
DE602004029496D1 (de) * 2003-12-22 2010-11-18 Novo Nordisk As Offbehälter zur lagerung von pharmazeutischen flüssigkeiten
WO2005067898A2 (en) 2004-01-07 2005-07-28 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
WO2005097175A2 (en) 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
WO2007046834A2 (en) 2004-12-22 2007-04-26 Centocor, Inc. Glp-1 agonists, compositions, methods and uses
US7879361B2 (en) 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
WO2007038540A1 (en) 2005-09-26 2007-04-05 Medtronic, Inc. Prosthetic cardiac and venous valves
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
MY144556A (en) 2005-10-24 2011-09-30 Nestec Sa Dietary fiber formulation and method of administration
BRPI0520704A2 (pt) 2005-11-30 2009-05-19 Generex Pharm Inc formulação farmacêutica absorvida oralmente e método de administração
US20100029558A1 (en) 2005-12-06 2010-02-04 Bristow Cynthia L Alpha1 proteinase inhibitor peptides methods and use
CN101454019A (zh) * 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
CA2652989A1 (en) 2006-06-08 2007-12-13 Diabecore Medical Inc. Derivatized insulin oligomers
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
EP2076242B8 (en) * 2006-07-27 2013-02-20 Nektar Therapeutics Aerosolizable formulation comprising insulin for pulmonary delivery
WO2008124522A2 (en) 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
US20090324609A1 (en) 2007-08-09 2009-12-31 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
US8575096B2 (en) 2007-08-13 2013-11-05 Novo Nordisk A/S Rapid acting insulin analogues
ES2612736T3 (es) * 2007-11-16 2017-05-18 Novo Nordisk A/S Composiciones farmacéuticas estables que comprenden liraglutida y degludec
CA2711561A1 (en) * 2008-01-04 2009-07-16 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
MX2010009033A (es) 2008-02-19 2010-12-21 Biocon Ltd Un metodo para obtener insulinas heterologas purificadas expresadas en levadura.
US8329419B2 (en) 2008-05-23 2012-12-11 Amylin Pharmaceuticals, Llc GLP-1 receptor agonist bioassays
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US20100069292A1 (en) 2008-09-02 2010-03-18 Biodel, Inc. Insulin with a basal release profile
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
CN117547538A (zh) 2009-02-13 2024-02-13 勃林格殷格翰国际有限公司 包含dpp-4抑制剂(利格列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
US8709400B2 (en) 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
MX2012001141A (es) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Composicion de insulina de accion prolongada.
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
EP3345593B1 (de) 2009-11-13 2023-09-06 Sanofi-Aventis Deutschland GmbH Pharmazeutische zusammensetzung umfassend despro36exendin-4(1-39)-lys6-nh2 und methionin
US20110118178A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
ES2398012T5 (es) 2009-11-13 2020-02-26 Sanofi Aventis Deutschland Lixisenatide como terapia complementaria a insulina glargina y metformina para tratar diabetes de tipo 2
US20110118180A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
CN102933200B (zh) 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
WO2011103575A1 (en) 2010-02-22 2011-08-25 Case Western Reserve University Long-acting insulin analogue preparations in soluble and crystalline forms
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
TW201141513A (en) 2010-04-14 2011-12-01 Sanofi Aventis Insulin-siRNA conjugates
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2011144674A2 (en) 2010-05-20 2011-11-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
US9085757B2 (en) 2010-06-17 2015-07-21 Regents Of The University Of Minnesota Production of insulin producing cells
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
PL2632478T3 (pl) 2010-10-27 2020-03-31 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
WO2012065996A1 (en) 2010-11-15 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN
WO2012066086A1 (en) 2010-11-17 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
JP6381914B2 (ja) 2011-02-02 2018-08-29 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者における低血糖の予防
CA2852056C (en) 2011-03-11 2021-08-10 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
EP2763691A1 (en) 2011-10-04 2014-08-13 Sanofi-Aventis Deutschland GmbH Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract

Similar Documents

Publication Publication Date Title
JP2011241213A5 (ja)
HRP20181028T1 (hr) Dugodjelujuće formulacije inzulina
AR081254A1 (es) Composicion farmaceutica que comprende ave0010 e insulina glargina
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
RU2015137674A (ru) Стабилизированные фармацевтические составы аналогов инсулина и/или производные инсулина
EA201590759A1 (ru) Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина
TN2016000500A1 (en) Composition for Treating Diabetes Comprising Long-acting lnsulin Analogue Conjugale and Long-acting lnsulinotropic Peptide Conjugale
CY1113755T1 (el) Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2
JP2016539921A5 (ja)
RU2019133674A (ru) Лечение сахарного диабета с помощью составов инсулинов длительного действия
JP2011225596A5 (ja)
NZ600477A (en) Insulin analogues with chlorinated amino acids
MX2013011174A (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
BR112013019744A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
JP2009500045A5 (ja)
JP2011528333A5 (ja)
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
MX360304B (es) Composiciones de activador de glucocinasa para el tratamiento de la diabetes.
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
JP2017502074A5 (ja)
RU2016114098A (ru) Новое производное аналога инсулина
EA201792030A1 (ru) Лечение пациентов с сахарным диабетом 2 типа
JP2014504601A5 (ja)